Muthu Sathish, Bapat Asawari, Jain Rashmi, Jeyaraman Naveen, Jeyaraman Madhan
Department of Orthopaedics, Government Hospital, Velayuthampalayam, Karur, Tamil Nadu, India.
Department of Biotechnology, School of Engineering and Technology, Sharda University, Greater Noida, Uttar Pradesh, India.
Stem Cell Investig. 2021 Apr 2;8:7. doi: 10.21037/sci-2020-037. eCollection 2021.
The recent advances in translational and nanomedicine have paved the way for developing the targeted drug delivery system at a greater pace among global researchers. On par with these technologies, exosomes act as a potential portal for cell-free drug delivery systems as these are bestowed with the native characteristics of the parent cell of origin. Exosomes, called extracellular vesicles (EcVs), are present in almost all cells, tissues, and body fluids. They help in intercellular signaling and maintains tissue homeostasis in the disease pathobiology. Researchers have characterized 9,769 proteins, 2,838 miRNAs, 3,408 mRNAs, and 1,116 lipids being present in exosomal cargo. The separation of exosomes from cells, tissues, and body fluids follow different patterned kinetics. Exosomes interact with the recipient cells through their surface receptor molecules and ligands and internalize within recipient cells through micropinocytosis and phagocytosis. Advancing technologies in regenerative medicine have facilitated the researchers to isolate exosomes from mesenchymal stem cells (MSCs) as these cells are blessed with supreme regenerative potentiality in targeting a disease. Exosomal cargo is a key player in establishing the diagnosis and executing therapeutic role whilst regulating a disease process. Various studies have exhibited the safety, efficacy, and therapeutic potentiality of exosomes in various cancers, neurodegenerative, cardiovascular, and orthopedic diseases. This article throws light on the composition, therapeutic role, and regulatory potentials of exosomes with the widening of the horizon in the field of regenerative medicine.
转化医学和纳米医学的最新进展为全球研究人员更快地开发靶向药物递送系统铺平了道路。与这些技术相当的是,外泌体作为无细胞药物递送系统的潜在通道,因为它们具有其来源母细胞的天然特性。外泌体,也称为细胞外囊泡(EcVs),几乎存在于所有细胞、组织和体液中。它们有助于细胞间信号传导,并在疾病病理生物学中维持组织稳态。研究人员已经鉴定出存在于外泌体货物中的9769种蛋白质、2838种miRNA、3408种mRNA和1116种脂质。从细胞、组织和体液中分离外泌体遵循不同的模式动力学。外泌体通过其表面受体分子和配体与受体细胞相互作用,并通过微胞饮作用和吞噬作用内化到受体细胞内。再生医学技术的进步促使研究人员从间充质干细胞(MSC)中分离外泌体,因为这些细胞在靶向疾病方面具有卓越的再生潜力。外泌体货物在建立诊断、发挥治疗作用以及调节疾病过程中起着关键作用。各种研究已经展示了外泌体在各种癌症、神经退行性疾病、心血管疾病和骨科疾病中的安全性、有效性和治疗潜力。随着再生医学领域视野的拓宽,本文阐明了外泌体的组成、治疗作用和调节潜力。